Edwards Reports Superior TAVR Results Compared To Clinical Surveillance In At-Risk Feature

By Reuters News

- Edwards Lifesciences Corporation EW.N:

  • PROGRESS TRIAL DEMONSTRATES EDWARDS TAVR IS SUPERIOR TO CLINICAL SURVEILLANCE FOR MODERATE AS PATIENTS WITH AT-RISK FEATURES

  • EDWARDS LIFESCIENCES CORPORATION - TAVR DELIVERS OVER 30% REDUCTION IN DEATH OR HEART FAILURE EVENTS VERSUS CLINICAL SURVEILLANCE

  • EDWARDS LIFESCIENCES CORPORATION - TAVR SHOWS NO MORTALITY AND NO DISABLING STROKES AT 30 DAYS

  • EDWARDS LIFESCIENCES CORPORATION - TAVR REDUCES HEART FAILURE HOSPITALIZATIONS BY OVER 50% AND IMPROVES QUALITY OF LIFE

  • EDWARDS LIFESCIENCES CORPORATION - TAVR SHOWS 33% RELATIVE REDUCTION IN DEATH OR HEART FAILURE EVENTS AT TWO YEARS

  • EDWARDS LIFESCIENCES CORPORATION - TAVR PATIENTS SHOW 15.5-POINT IMPROVEMENT IN QUALITY OF LIFE AT 30 DAYS

Further company coverage: EW.N

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.